16.49 USD
↘ 0.19 (1.14%)AT CLOSE (11:59 AM EDT)
Nurix Therapeutics, Inc. Common stock
NRIXNASDAQ • USD
16.53
↗ 0.04 (0.26%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
16.53
↗ 0.04 (0.26%)
Market: CLOSED
Open?$16.52
High?$17.15
Low?$16.43
Prev. Close?$16.68
Volume?615.6K
Avg. Volume?1.3M
VWAP?$16.68
Rel. Volume?0.48x
Bid / Ask
Bid?$16.06 × 300
Ask?$17.01 × 500
Spread?$0.95
Midpoint?$16.54
Valuation & Ratios
Market Cap?1.7B
Shares Out?103.4M
Float?88.6M
Float %?86.2%
P/E Ratio?N/A
P/B Ratio?3.55
EPS?-$2.86
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?6.01Strong
Quick Ratio?6.01Strong
Cash Ratio?0.77Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?3.55FAIR▾
P/S?23.76HIGH▾
P/FCF?N/A▾
EV/EBITDA?-5.3CHEAP▾
EV/Sales?22.76HIGH▾
Returns & Efficiency
ROE?-61.4%WEAK▾
ROA?-46.4%WEAK▾
Cash Flow & Enterprise
FCF?$-271854000
Enterprise Value?$1.6B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Address
1600 SIERRA POINT PKWY
BRISBANE, CA 94005
Phone: (415) 660-5320
BRISBANE, CA 94005
Phone: (415) 660-5320